Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CATCHAML
NCT04318678Phase 1Recruiting
- Sponsor
- St. Jude Children's Research Hospital
- Start
- Jul 2020
- Primary completion
- Jul 2029
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label trial of CD123-specific CAR T-cell therapy (St. Jude Children's Research Hospital) in acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), acute lymphoblastic leukemia (ALL) and 2 more (2 arms), sponsored by St. Jude Children's Research Hospital. Primary endpoint: Maximum Tolerated Dose at 4 weeks. Started Jul 2020; status: recruiting.
02
Drugs
CD123-specific CAR T-cell therapy (St. Jude Children's Research Hospital)
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)acute lymphoblastic leukemia (ALL)blastic plasmacytoid dendritic cell neoplasm (BPDCN)mixed phenotype acute leukemia (MPAL)
Beyond the preview
Go deeper on NCT04318678.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04318678.